Information  X 
Enter a valid email address

Evgen Pharma PLC (EVG)

  Print      Mail a friend

Tuesday 17 December, 2019

Evgen Pharma PLC

Investor presentation

RNS Number : 0471X
Evgen Pharma PLC
17 December 2019
 

Evgen Pharma plc

("Evgen Pharma" or "the Company")

 

Investor presentation

 

Evgen Pharma (AIM: EVG) a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces it will hold an investor briefing on Tuesday, 14 January 2020.

 

The event will take place in the Copper Bar, upstairs at Balls Brothers, 6 Adams Court, Old Broad St, London EC2N 1DX at 4.30pm for a 4.45pm start. This will be followed by drinks and canapés, and a chance to network. Dr Stephen Franklin, CEO and Richard Moulson CFO, will provide a presentation on the Half Year Report including an overview of the Company's strategy.

 

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

Enquiries:

 

Evgen Pharma plc www.evgen.com 

via Walbrook

Dr Stephen Franklin, CEO 


Richard Moulson, CFO 




finnCap www.finncap.com 

+44 (0) 20 7220 0500

Geoff Nash / Teddy Whiley (Corporate Finance) 


Alice Lane, Manasa Patil (ECM) 




WG Partners LLP 

+44 (0) 20 3705 9330

Nigel Barnes / Claes Spång  




Walbrook PR 

+44 (0)20 7933 87870 or [email protected]

Paul McManus / Anna Dunphy 

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About Evgen Pharma plc 

Evgen Pharma is a clinical stage company developing sulforaphane based medicines for the treatment of multiple diseases The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.  

 

The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. Our lead product, SFX-01, has demonstrated efficacy in a Phase II trial for advanced metastatic breast cancer. It has been used to treat over 150 patients in clinical trials and is well-tolerated with predominately mild side-effects.

 

Evgen shares are traded on the AIM market of the London Stock under the ticker symbol EVG. 

 

For further information, please visit: www.evgen.com 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRAFMMMZVVZGLZM

a d v e r t i s e m e n t